In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including:

• 3 bispecific antibodies approved for the treatment of R/R MM that target BCMA or GPRC5D
• The role of bispecific antibodies in R/R MM
• Safety considerations for patients while receiving a bispecific antibody
• Emerging data and clinical trials with bispecific antibodies
• Key clinical pearls for optimal use of bispecific antibodies

Presenter:

Caitlin Costello, MD
Clinical Professor of Medicine
Director, Multiple Myeloma Program
Division of Blood and Marrow Transplantation
Moores Cancer Center
UC San Diego
La Jolla, California

Link to full program:
https://bit.ly/40bjFCZ

In this episode, Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss important topics related to gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including:

• The diagnosis and typical presenting symptoms of GEP-NETs
• Findings from recent key phase III studies including NETTER-2 and CABINET
• Recommendations for treatment sequencing
• Notable clinical pearls regarding GEP-NET therapies
• Current guidelines for GEP-NET care and monitoring

Presenters:

Thor R. Halfdanarson, MD
Consultant, Division of Medical Oncology
Professor of Oncology
Associate Professor of Medicine
Mayo Clinic Comprehensive Cancer Center
Chair, Hepato-Pancreatico-Biliary Disease Group
Rochester, Minnesota

Jonathan Strosberg
Professor, GI Oncology
Chair, Neuroendocrine Tumor Division
Moffitt Cancer Center and Research Institute
Tampa, Florida

Link to full program:
https://bit.ly/3Y0JWBa

In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including:

• Phase III PRIMA/ENGOT-OV26/GOG-3012 Final OS Results: Niraparib as First-Line Maintenance in Advanced Ovarian Cancer
• ATHENA COMBO/GOG-3020/ENGOT-ov45: Rucaparib With or Without Nivolumab Maintenance in Newly Diagnosed Ovarian Cancer
• Phase II PICCOLO Trial of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer With High-FRα Expression
• Phase III KEYNOTE-B21/GOG-3053 Study of Adjuvant Chemotherapy With or Without Radiotherapy With or Without Pembrolizumab in Patients With Newly Diagnosed Endometrial Cancer or Carcinosarcoma After Curative Surgery With no Residual Disease
• Phase III KEYNOTE-A18 Overall Survival Results: Pembrolizumab Plus Concurrent Chemoradiation in High-Risk Locally Advanced Cervical Cancer
  

Program faculty:

Ana Oaknin, MD, PhD
Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Alexandra Leary, MD, PhD
Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab,
Institut Gustave Roussy
Paris, France

Resources:
To download the slides associated with this podcast discussion, please visit the program page.